Q1 EPS Estimate for Bristol-Myers Squibb Boosted by Analyst

Bristol-Myers Squibb (NYSE:BMY - Free Report) - Equities researchers at Zacks Research raised their Q1 2026 earnings per share (EPS) estimates for Bristol-Myers Squibb in a research note issued to investors on Thursday, June 12th. Zacks Research analyst E. Bagri now forecasts that the biopharmaceutical company will earn $1.42 per share for the quarter, up from their previous forecast of $1.41. The consensus estimate for Bristol-Myers Squibb's current full-year earnings is $6.74 per share. Zacks Research also issued estimates for Bristol-Myers Squibb's Q2 2026 earnings at $1.54 EPS and Q1 2027 earnings at $1.42 EPS.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, beating analysts' consensus estimates of $1.50 by $0.30. The business had revenue of $11.20 billion for the quarter, compared to the consensus estimate of $10.77 billion. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. The business's revenue for the quarter was down 5.6% on a year-over-year basis. During the same quarter in the prior year, the business posted ($4.40) EPS.

Other equities research analysts have also recently issued reports about the stock. Wall Street Zen cut shares of Bristol-Myers Squibb from a "strong-buy" rating to a "buy" rating in a research report on Friday, June 6th. The Goldman Sachs Group reissued a "neutral" rating and issued a $55.00 target price (down from $67.00) on shares of Bristol-Myers Squibb in a report on Tuesday, April 8th. Piper Sandler started coverage on Bristol-Myers Squibb in a research note on Tuesday, April 22nd. They set an "overweight" rating and a $65.00 price target on the stock. Jefferies Financial Group cut their price target on Bristol-Myers Squibb from $70.00 to $68.00 and set a "buy" rating on the stock in a research report on Wednesday, April 23rd. Finally, UBS Group decreased their price objective on Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating for the company in a report on Friday, April 11th. Two investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, Bristol-Myers Squibb currently has a consensus rating of "Hold" and a consensus target price of $58.00.

Bristol-Myers Squibb Trading Down 1.9%

Shares of Bristol-Myers Squibb stock opened at $49.71 on Monday. The company has a current ratio of 1.25, a quick ratio of 1.15 and a debt-to-equity ratio of 2.90. The company has a fifty day simple moving average of $48.71 and a 200-day simple moving average of $54.70. The stock has a market cap of $101.15 billion, a price-to-earnings ratio of -11.25, a PEG ratio of 2.07 and a beta of 0.38. Bristol-Myers Squibb has a 12-month low of $39.35 and a 12-month high of $63.33.

Insider Transactions at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, EVP Samit Hirawat acquired 4,250 shares of the stock in a transaction on Friday, April 25th. The shares were bought at an average price of $47.58 per share, with a total value of $202,215.00. Following the acquisition, the executive vice president now owns 83,513 shares of the company's stock, valued at $3,973,548.54. This trade represents a 5.36% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.09% of the company's stock.

Institutional Trading of Bristol-Myers Squibb

Several hedge funds have recently modified their holdings of BMY. Vanguard Group Inc. boosted its position in shares of Bristol-Myers Squibb by 0.8% during the 1st quarter. Vanguard Group Inc. now owns 191,403,004 shares of the biopharmaceutical company's stock worth $11,673,669,000 after purchasing an additional 1,458,488 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in Bristol-Myers Squibb by 0.5% during the first quarter. Charles Schwab Investment Management Inc. now owns 60,606,905 shares of the biopharmaceutical company's stock worth $3,696,415,000 after buying an additional 306,430 shares in the last quarter. Capital International Investors grew its position in Bristol-Myers Squibb by 7.5% during the fourth quarter. Capital International Investors now owns 45,866,624 shares of the biopharmaceutical company's stock worth $2,593,940,000 after buying an additional 3,218,865 shares during the period. Geode Capital Management LLC increased its holdings in Bristol-Myers Squibb by 2.7% in the fourth quarter. Geode Capital Management LLC now owns 44,391,247 shares of the biopharmaceutical company's stock valued at $2,505,967,000 after buying an additional 1,187,231 shares in the last quarter. Finally, Norges Bank acquired a new stake in shares of Bristol-Myers Squibb during the 4th quarter valued at approximately $1,989,525,000. 76.41% of the stock is owned by institutional investors and hedge funds.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.